Abstract:Human microbiomes, particularly in the gut, could have a major impact on the efficacy and toxicity of drugs. However, gut microbial metabolism is often neglected in the drug discovery and development process. Medicen, a Paris-based human health innovation cluster, has gathered more than 30 international leading experts from pharma, academia, biotech, clinical research organizations, and regulatory science to develop proposals to facilitate the integration of microbiome science into drug discovery and development. Seven subteams were formed to cover the complementary expertise areas of 1) pharma experience and case studies, 2) in silico microbiome–drug interaction, 3) in vitro microbial stability screening, 4) gut fermentation models, 5) animal models, 6) microbiome integration in clinical and regulatory aspects, and 7) microbiome ecosystems and models. Each expert team produced a state-of-the-art report of their respective field highlighting existing microbiome-related tools at every stage of drug discovery and development. The most critical limitations are the growing, but still limited, drug–microbiome interaction data to produce predictive models and the lack of agreed-upon standards despite recent progress. In this paper we will report on and share proposals covering 1) how microbiome tools can support moving a compound from drug discovery to clinical proof-of-concept studies and alert early on potential undesired properties stemming from microbiome-induced drug metabolism and 2) how microbiome data can be generated and integrated in pharmacokinetic models that are predictive of the human situation. Examples of drugs metabolized by the microbiome will be discussed in detail to support recommendations from the working group. SIGNIFICANCE STATEMENT Gut microbial metabolism is often neglected in the drug discovery and development process despite growing evidence of drugs' efficacy and safety impacted by their interaction with the microbiome. This paper will detail existing microbiome-related tools covering every stage of drug discovery and development, current progress, and limitations, as well as recommendations to integrate them into the drug discovery and development process.

Similarity of drug targets to human microbiome metaproteome promotes pharmacological promiscuity

Extensive impact of non-antibiotic drugs on human gut bacteria

Mapping human microbiome drug metabolism by gut bacteria and their genes

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

G protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain interactions

Interplays between drugs and the gut microbiome

Human Gut Microbiota and Drug Metabolism

Integrating the gut microbiome and pharmacology

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules

High-throughput transcriptomics of 409 bacteria–drug pairs reveals drivers of gut microbiota perturbation

Human xenobiotic metabolism proteins have full-length and split homologs in the gut microbiome

Nutrient Competition Predicts Gut Microbiome Restructuring under Drug Perturbations

Advancing functional and translational microbiome research using meta-omics approaches

The metabolic effect of gut microbiota on drugs

Systematic mapping of drug metabolism by the human gut microbiome

Targeting the Human Genome-Microbiome Axis for Drug Discovery: Inspirations from Global Systems Biology and Traditional Chinese Medicine.

The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response

Emergence of community behaviors in the gut microbiota upon drug treatment

Microbial metabolites: cause or consequence in gastrointestinal disease?